Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maxitrol (neomycin sulfate, polymyxin B sulfate, and dexamethasone) is an FDA-approved ophthalmic combination drug used to treat steroid-responsive inflammatory ocular conditions where bacterial infection or a risk of infection exists. It contains two antibiotics—neomycin, which inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and polymyxin B, which disrupts the bacterial cytoplasmic membrane—alongside dexamethasone, a potent corticosteroid that suppresses the inflammatory response. This combination is typically administered as an ophthalmic suspension or ointment for conditions such as conjunctivitis, keratitis, and chronic anterior uveitis. The J Molner is a developer of generic versions of this product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neomycin + polymyxin b + dexamethasone.